Please assess the completion status of the following clinical trial:

Trial Title: A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects 18 to 65 years of age (inclusive)~* Diagnosis of RA~* Swollen joint count of ≥6 out of 66 joints and tender joint count of ≥6 out of 68 joints~* Seropositivity based on either a positive rheumatoid factor or anti cyclic citrullinated peptide antibody at screening -OR- known erosive disease based on previous X-ray report or erosions detected on screening hand and foot X-ray~* Baseline CRP level or Westergren erythrocyte sedimentation rate ≥1.2 × upper limit of normal~* Receiving stable therapy with 1 of the following DMARDs: methotrexate, sulfasalazine, leflunomide, anti-malarial drug, or penicillamine~* Palpable 2+ synovitis of the wrist or ≥2 MCPs in the MRI-designated hand~Exclusion Criteria:~* History or presence of a clinically significant medical disorder other than RA that, in the opinion of the investigator and medical monitor, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.~* Inflammatory, rheumatological disorders other than RA, where arthritis may be a prominent feature~* Planned surgery during the study~* History of alcohol or drug abuse, or excessive alcohol consumption~* History of tuberculosis (TB) infection of any kind (pulmonary or extrapulmonary, active or latent), regardless of history of anti-TB treatment.~* Pregnant or nursing an infant or with a life partner who is pregnant, nursing, or planning to become pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- VX-509 100 mg qd Arm (Type: EXPERIMENTAL): None
- VX-509 200 mg qd Arm (Type: EXPERIMENTAL): None
- VX-509 300 mg qd Arm (Type: EXPERIMENTAL): None
- Placebo Arm (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).